|
1
|
Prat A and Perou CM: Deconstructing the
molecular portraits of breast cancer. Mol Oncol. 5:5–23. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cancer Genome Atlas Network, .
Comprehensive molecular portraits of human breast tumours. Nature.
490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gándara-Cortes M, Vázquez-Boquete Á,
Fernández-Rodríguez B, Viaño P, Ínsua D, Seoane-Seoane A, Gude F,
Gallego R, Fraga M, Antúnez JR, et al: Breast cancer subtype
discrimination using standardized 4-IHC and digital image analysis.
Virchows Arch. 472:195–203. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Subik K, Lee JF, Baxter L, Strzepek T,
Costello D, Crowley P, Xing L, Hung MC, Bonfiglio T, Hicks DG and
Tang P: The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67
and AR by immunohistochemical analysis in breast cancer cell lines.
Breast Cancer (Auckl). 4:35–41. 2010.PubMed/NCBI
|
|
5
|
Voduc KD, Cheang MC, Tyldesley S, Gelmon
K, Nielsen TO and Kennecke H: Breast cancer subtypes and the risk
of local and regional relapse. J Clin Oncol. 28:1684–1691. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gradishar WJ, Anderson BO, Balassanian R,
Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A,
Giordano SH, et al: Invasive breast cancer version 1.2016, NCCN
clinical practice guidelines in oncology. J Natl Compr Canc Netw.
14:324–354. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mohsenifar J, Almassi-Aghdam M,
Mohammad-Taheri Z, Zare K, Jafari B, Atri M, Mortazavi SH, Azadeh
P, Bagherzadeh M, Azargashb E and Rahimi F: Prognostic values of
proliferative markers ki-67 and repp86 in breast cancer. Arch Iran
Med. 10:27–31. 2007.PubMed/NCBI
|
|
8
|
Kontzoglou K, Palla V, Karaolanis G,
Karaiskos I, Alexiou I, Pateras I, Konstantoudakis K and Stamatakos
M: Correlation between Ki67 and breast cancer prognosis. Oncology.
84:219–225. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhao S, Xu L, Liu W, Lv C, Zhang K, Gao H,
Wang J and Ma R: Comparison of the expression of prognostic
biomarkers between primary tumor and axillary lymph node metastases
in breast cancer. Int J Clin Exp Pathol. 8:5744–5748.
2015.PubMed/NCBI
|
|
10
|
Wolff AC, Hammond ME, Hicks DG, Dowsett M,
McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M,
Fitzgibbons P, et al: Recommendations for human epidermal growth
factor receptor 2 testing in breast cancer: American society of
clinical oncology/college of American pathologists clinical
practice guideline update. J Clin Oncol. 31:3997–4013. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Goldhirsch A, Winer EP, Coates AS, Gelber
RD, Piccart-Gebhart M, Thürlimann B and Senn HJ; Panel members, :
Personalizing the treatment of women with early breast cancer:
Highlights of the St Gallen international expert consensus on the
primary therapy of early breast cancer 2013. Ann Oncol.
24:2206–2223. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yao ZX, Lu LJ, Wang RJ, Jin LB, Liu SC, Li
HY, Ren GS, Wu KN, Wang DL and Kong LQ: Discordance and clinical
significance of ER, PR, and HER2 status between primary breast
cancer and synchronous axillary lymph node metastasis. Med Oncol.
31:7982014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Song JL, Chen C, Yuan JP and Sun SR:
Progress in the clinical detection of heterogeneity in breast
cancer. Cancer Med. 5:3475–3488. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liedtke C, Broglio K, Moulder S, Hsu L,
Kau SW, Symmans WF, Albarracin C, Meric-Bernstam F, Woodward W,
Theriault RL, et al: Prognostic impact of discordance between
triple-receptor measurements in primary and recurrent breast
cancer. Ann Oncol. 20:1953–1958. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sari E, Guler G, Hayran M, Altundag K,
Gullu I and Ozisik Y: Comparison of ER, PR, HER2 in primary and
paired relapsed/metastatic lesions of metastatic breast cancer
patients. J Clin Oncol. 27:10632009. View Article : Google Scholar
|
|
16
|
Niikura N, Liu J, Hayashi N, Mittendorf
EA, Gong Y, Palla SL, Tokuda Y, Gonzalez-Angulo AM, Hortobagyi GN
and Ueno NT: Loss of human epidermal growth factor receptor 2
(HER2) expression in metastatic sites of HER2-overexpressing
primary breast tumors. J Clin Oncol. 30:593–599. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dieci MV, Barbieri E, Piacentini F,
Ficarra G, Bettelli S, Dominici M, Conte PF and Guarneri V:
Discordance in receptor status between primary and recurrent breast
cancer has a prognostic impact: A single-institution analysis. Ann
Oncol. 24:101–108. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Curtit E, Nerich V, Mansi L, Chaigneau L,
Cals L, Villanueva C, Bazan F, Montcuquet P, Meneveau N, Perrin S,
et al: Discordances in estrogen receptor status, progesterone
receptor status, and HER2 status between primary breast cancer and
metastasis. Oncologist. 18:667–674. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Aktas B, Kasimir-Bauer S, Müller V, Janni
W, Fehm T, Wallwiener D, Pantel K and Tewes M; DETECT Study Group,
: Comparison of the HER2, estrogen and progesterone receptor
expression profile of primary tumor, metastases and circulating
tumor cells in metastatic breast cancer patients. BMC Cancer.
16:5222016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Turner N, Pestrin M, Galardi F, De Luca F,
Malorni L and Di Leo A: Can biomarker assessment on circulating
tumor cells help direct therapy in metastatic breast cancer?
Cancers (Basel). 6:684–707. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nedergaard L, Haerslev T and Jacobsen GK:
Immunohistochemical study of estrogen receptors in primary breast
carcinomas and their lymph node metastases including comparison of
two monoclonal antibodies. APMIS. 103:20–24. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Aitken SJ, Thomas JS, Langdon SP, Harrison
DJ and Faratian D: Quantitative analysis of changes in ER, PR and
HER2 expression in primary breast cancer and paired nodal
metastases. Ann Oncol. 21:1254–1261. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Feng T, Zhang J and Zhong L: Relationship
of ER and HER-2 expression in primary tumor and axillary lymph node
metastases of invasive ductal breast cancer. Chin J Gen Surg.
2012.
|
|
24
|
Kinoe H, Yamanouchi K, Kuba S, Morita M,
Sakimura C, Kanetaka K, Takatsuki M, Abe K, Yano H, Matsumoto M, et
al: Discordance of hormone receptor, human epidermal growth factor
receptor-2, and Ki-67 between primary breast cancer and synchronous
axillary lymph node metastasis. J BUON. 23:60–66. 2018.PubMed/NCBI
|
|
25
|
Santinelli A, Pisa E, Stramazzotti D and
Fabris G: HER-2 status discrepancy between primary breast cancer
and metastatic sites. Impact on target therapy. Int J Cancer.
122:999–1004. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ataseven B, Gologan D, Gunesch A, Kehl V,
Hoegel B, Beer M and Eiermann W: HER2/neu, topoisomerase 2a,
estrogen and progesterone receptors: Discordance between primary
breast cancer and metastatic axillary lymph node in expression and
amplification characteristics. Breast Care (Basel). 7:465–470.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jensen JD, Knoop A, Ewertz M and Laenkholm
AV: ER, HER2, and TOP2A expression in primary tumor, synchronous
axillary nodes, and asynchronous metastases in breast cancer.
Breast Cancer Res Treat. 132:511–521. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
D'Andrea MR, Limiti MR, Bari M,
Zambenedetti P, Montagutti A, Ricci F, Pappagallo GL, Sartori D,
Vinante O and Mingazzini PL: Correlation between genetic and
biological aspects in primary non-metastatic breast cancers and
corresponding synchronous axillary lymph node metastasis. Breast
Cancer Res Treat. 101:279–284. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jung J, Lee SH, Park M, Youn JH, Shin SH,
Gwak HS and Yoo H: Discordances in ER, PR, and HER2 between primary
breast cancer and brain metastasis. J Neurooncol. 137:295–302.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sighoko D, Liu J, Hou N, Gustafson P and
Huo D: Discordance in hormone receptor status among primary,
metastatic, and second primary breast cancers: Biological
difference or misclassification? Oncologist. 19:592–601. 2014.
View Article : Google Scholar : PubMed/NCBI
|
